The NTD Drug Discovery Booster project aims to speed up the process and cut the cost of finding new treatments for leishmaniasis and Chagas disease, which 450 million people are at risk of contracting worldwide.
Since 2018, the project brings together DNDi and eight pharmaceutical companies (AbbVie, Astellas Pharma Inc., AstraZeneca, Celgene Corporation (now Bristol-Myers Squibb), Eisai Co., Ltd., Merck KGaA, Shionogi & Co., Ltd., and Takeda Pharmaceutical Company Limited).
This video explains how the Drug Discovery Booster uses a multilateral, simultaneous and iterative search process to speed up the screening for potential treatments. With this approach, the project will significantly shorten the time it will take to find new treatment leads.
